The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

Cambridge biotech Nuclera has agreed a collaboration with Danaher company and international life sciences leader Cytiva – ...

US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

Backed by major investors, Volare’s new facility will turn food waste into sustainable insect protein and help boost Europe’s ...

AbbVie (NYSE: ABBV) in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the ...

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 pathway ...

At the recent F&A Next conference in Wageningen, the Feike Sijbesma Sustainable Innovation Award 2025 was granted to two ...